Journal
ONCOIMMUNOLOGY
Volume 3, Issue 1, Pages -Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.27414
Keywords
anticancer immunity; anticancer therapy; epigenetic regulatory agent; HDACi; immunogenic cell death; immunotherapy
Categories
Ask authors/readers for more resources
Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon gamma (IFN gamma). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
